# A Phase II Study of Bintrafusp Alfa (M7824) in Checkpoint Inhibitor Naive and Refractory Subjects With Urothelial Carcinoma

> **NCT04501094** · PHASE2 · TERMINATED · sponsor: **National Cancer Institute (NCI)** · enrollment: 2 (actual)

## Conditions studied

- Urothelial Cancer

## Interventions

- **DRUG:** Bintrafusp alfa (M7824)

## Key facts

- **NCT ID:** NCT04501094
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2020-10-26
- **Primary completion:** 2021-01-19
- **Final completion:** 2021-10-13
- **Target enrollment:** 2 (ACTUAL)
- **Why stopped:** Because of the low accrual and the safety concerns we closed the study.
- **Last updated:** 2022-03-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04501094

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04501094, "A Phase II Study of Bintrafusp Alfa (M7824) in Checkpoint Inhibitor Naive and Refractory Subjects With Urothelial Carcinoma". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT04501094. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*